Glycan excellence against cancer
About Us

Tacalyx was founded in 2019 as a spin-out of the Max-Planck-Institute of Colloids and Interfaces (MPICI) in Potsdam, Germany, with the help of Prof. Dr. Peter Seeberger and Dr. Oren Moscovitz.
We strive to develop novel anticancer therapeutics targeting Tumor Associated Carbohydrate Antigens (TACAs).

Team

Alena Horn
Office Manager
Francesco Muraca, PhD
Head of Cell Biology
Gustavo Moreira, PhD
Head of Antibody and Protein Biochemistry
Kajo Wiest
Head of Finance & Administration
Karla Soto, PhD
Scientist Cell Based Assays
Prof. Matthias Ocker, MD
Head of Experimental Medicine
Peter Sondermann, PhD
CEO
Samina Naz
Research Associate
Wiebke Winkler, PhD
Scientist Antibody Generation

Board of Directors

Dr. Klaus Schollmeier
Chairman of the Board
Tim Brans
coparion
Evan Castiglia
Thuja Capital
Dr. Frank Hensel
High-Tech Gründerfonds
Ulrich Mahr
Max-Planck-Innovation GmbH
Dr. Peter Neubeck
Kurma Partners
Karlheinz Schmelig
Creathor Ventures
Prof. Dr. Peter Seeberger
Max-Planck-Institute for Colloids and Interfaces

Investors

Technology
Tumor-Associated Carbohydrate Antigens (TACAs)

TACAs are attractive targets for novel immunotherapeutics against human cancers. Many TACAs are expressed during embryonic development but not under physiologic conditions in differentiated tissues. On tumors, in contrast, TACAs show very high expression levels, allowing to bring more therapeutic agents to the cancer cell.

Pipeline

Our pipeline comprises several first-in-class assets targeting different TACAs across multiple solid human cancers.
Assets in our pipeline are amenable to various treatment modalities, including antibody-drug conjugates, T cell engagers and others.

News

Apr 23 2025, 12:00
AACR Annual Meeting 2025 in Chicago
Apr 08 2025, 12:00
We are hiring!
Download document
Feb 28 2025, 12:00
We are hiring!
Download document
News Archive
Careers

We are a growing team of highly motivated scientists. We endorse the biotech spirit of problem solving and let the best idea win. Being innovative and focused is key to have fast decisions and optimized solutions for our early pipeline.
Located in one of Berlin's prestigious science hubs, we offer a vibrant research environment at the forefront of antibody drug development.

Please follow the link for current job offers.
Unsolicited applications are welcome!

Current Job Offers

Contact

Phone
+49 30 407 237 10
Email
info@tacalyx.com
Tacalyx GmbH

Magnusstr. 11
12489 Berlin
Germany

Follow Us
Privacy Policy

Imprint